Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene

Acta Biochimica et Biophysica Sinica

Volumn 37, Issue 5, 2005, Pages 310-316

  Zhou, Xiu Min ^a,b   Lin, Ju Sheng ^a   Shi, Yi ^b   Tian, De An ^a   Huang, Huan Jun ^a   Zhou, He Jun ^a   Jin, You Xin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Hepatitis B virus surface gene (HBs gene); RNA interference (RNAi); Small interference RNA (siRNA)

Indexed keywords

HEPATITIS B VIRUS;

HEPATITIS B SURFACE ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETICS; HELA CELL; HEPATITIS B; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

BASE SEQUENCE; FEASIBILITY STUDIES; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HELA CELLS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA;

EID: 23844434004     PISSN: 16729145     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2005.00049.x     Document Type: Article

References (24)

1. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003, 37: 764-770
2. Mancini M, Davis H, Tiollais P, Michel ML. DNA-based immunization against the envelope proteins of the hepatitis B virus. J Biotechnol 1996, 44: 47-57
3. Wang Y, Cui F, Lü Y, Li C, Xu X, Deng C, Wang D et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004, 39: 318-24
4. Nakamoto Y, Suda T, Momoi T, Kaneko S. Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 2004, 64: 3326-3333
5. Gagrica S, Hauser S, Kolfschoten I, Osterloh L, Agami R, Gaubatz S. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. EMBO J 2004, 23: 4627-4638
6. Cheng JC, Sakamoto KM. The emerging role of RNA interference in the design of novel therapeutics in oncology. Cell Cycle 2004, 3: 1398-401
7. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004, 6: 8184-8192
8. Pham JW, Pellino JL, Lee YS, Carthew RW, Sontheimer EJ. A Dicer-2-dependent 80S complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 117: 83-94
9. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208
10. Sohail M, Doran G, Riedemann J, Macaulay V, Southern EM. A simple and cost-effective method for producing small interfering RNAs with high efficacy. Nucleic Acids Res 2003, 31: e38
11. Wang L, Mu FY. A web-based design center for vector-based siRNA and siRNA cassette. Bioinformatics 2004, 20: 1818-1820
12. Kobayashi N, Matsui Y, Kawase A, Hirata K, Miyagishi M, Taira K, Nishikawa M et al. Vector-based in vivo RNA interference: Dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther 2004, 308: 688-93
13. Carreño V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992, 15: 102-106
14. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 1997, 25: 241-244
15. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24:714-717
16. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005, 102: 773-778
17. Ying C, de Clercq E, Neyts J. Selective inhibition of hepatitis B virus replication by RNA interference. Biochem Biophys Res Commun 2003, 309: 482-484
18. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21: 639-644
19. Luo KQ, Chang DC. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun 2004, 318: 303-310
20. Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 2004, 32: 691-699
21. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K. siDirect: Highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 2004, 32: W124-129
22. Henschel A, Buchholz F, Habermann B. DEQOR: A web-based tool for the design and quality control of siRNAs. Nucleic Acids Res 2004, 32: W113-120
23. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22: 326-330
24. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, Macaulay VM. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 2003, 278: 15991-15997